Improving treatments for head and neck cancers by targeting specific proteins
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
This study is looking at why some head and neck cancers don't respond well to current treatments, especially those that target a specific protein called EGFR, so that researchers can find better ways to help patients feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10889237 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of treatments for head and neck squamous cell carcinoma (HNSCC) by investigating the mechanisms behind resistance to existing therapies, particularly those targeting the epidermal growth factor receptor (EGFR). The team will conduct a series of experiments that include laboratory studies, preclinical testing, and analysis of clinical samples to identify how cancer cells evade treatment. By understanding these resistance mechanisms, they aim to develop new therapeutic strategies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who have experienced resistance to EGFR-targeted therapies.
Not a fit: Patients with head and neck cancers that do not involve EGFR or those who have not received prior EGFR-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with head and neck cancers, potentially overcoming current resistance to therapies.
How similar studies have performed: Previous research has shown promise in targeting EGFR and its related pathways, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Lemmon, Mark a — Yale University
- Study coordinator: Lemmon, Mark a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.